-
Mashup Score: 7Let's take steps together at PurpleStride! - 12 day(s) ago
PurpleStride is the ultimate event to end pancreatic cancer. Register for free and start fundraising today!
Source: secure.pancan.orgCategories: General Medicine NewsTweet
-
Mashup Score: 23Distinct molecular and clinical features of specific variants of KRAS codon 12 in pancreatic adenocarcinoma - 3 month(s) ago
Abstract. PURPOSE Oncogenic mutations in KRAS have been identified in > 85% of pancreatic ductal adenocarcinoma (PDAC) cases. G12D, G12V, and G12R are the most frequent variants. Using large clinical and genomic databases, this study characterizes prognostic and molecular differences between KRAS variants, focusing on KRAS G12D and G12R. METHODS PDAC samples were tested using DNA and RNA sequencing. MAPK activation score and tumor microenvironment were analyzed from RNA expression data. Real-world overall survival (OS) obtained from insurance claims data was calculated from tissue collection to last contact. Significance was determined by X2 and Fisher-Exact tests. RESULTS 3,755 PDAC patients harboring KRAS G12D (n = 1,766), G12V (n = 1,294) G12R (n = 621) or G12C (n = 74) variants were identified. Patients with G12R mutations had longer OS compared to G12D overall (12.7 vs 10.1 months, p-value=0.0001), with similar trends in patients treated with gemcitabine/nab-paclitaxel (13.5 vs 10
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
A success for our GI Oncology #SiteDiseaseGroup @SylvesterCancer, with Bach Ardalan leading this @CCR_AACR📖on distinct molecular➕clinical features of #KRAS G12 mutations, esp KRAS G12R, in #PancreaticCancer #pancsm! Builds on ongoing 🫱🏽🫲🏾 w/ @carisls POA https://t.co/eUvJthVODs
-
-
Mashup Score: 1Help me Challenge Cancer! - 3 month(s) ago
The DCC is a year-round collective community movement to raise money in support of Sylvester Comprehensive Cancer Center at the University of Miami. With your support, we are saving more lives. #OneTeamOneFight
Source: dolphinscancerchallenge.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/vv2gs2JLVe
-
-
Mashup Score: 17The Myeloid Network - 3 month(s) ago
Welcome
Source: themyeloidnetwork.eng.ucsd.eduCategories: General Medicine News, Hem/OncsTweet-
RT @JennGuerriero: Checkout the updated speaker list for #TheMyeloidNetwork on our website: https://t.co/k1V2K9InFi Including Drs. Karolina…
-
-
Mashup Score: 0Help me Challenge Cancer! - 5 month(s) ago
The DCC is a year-round collective community movement to raise money in support of Sylvester Comprehensive Cancer Center at the University of Miami. With your support, we are saving more lives. #OneTeamOneFight
Source: dolphinscancerchallenge.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/vv2gs2JLVe
-
-
Mashup Score: 6Dr. Jashodeep Datta Recognized with Prestigious Award from the American College of Surgeons - InventUM - 6 month(s) ago
Dr. Datta is the first member of the Miller School to receive the Joan L. and Julius H. Jacobson II Promising Investigator Award.
Source: news.med.miami.eduCategories: General Medicine News, Oncologists1Tweet-
Thx to @umiamimedicine @LauraCastroComm for amplifying this: https://t.co/tAOZp2wVzI CC: @AcademicSurgery @UnivSurg @AsianAcadSurg @PanCAN @letswinpc @SocSurgOnc @AHPBA @IHPBA #pancsm
-
-
Mashup Score: 23
Abstract. Purpose: Interleukin (IL)-1 pathway upregulation is implicated in pancreatic ductal adenocarcinoma (PDAC) progression, therapy resistance, and survival. Nadunolimab is an IL-1 receptor accessory protein (IL1RAP)-targeting antibody with enhanced antibody-dependent cellular cytotoxicity that blocks IL-1α/IL-1β signaling. We investigated efficacy and safety of nadunolimab in PDAC, in combination with gemcitabine/nab-paclitaxel (GN). Patients and methods: Patients with previously untreated locally advanced/metastatic PDAC received nadunolimab (1.0-7.5 mg/kg) every two weeks with standard GN. The primary objective was safety; secondary objectives were anti-tumor response, progression-free survival (PFS) and overall survival (OS). Correlations between serum and tumor biomarkers and clinical response were explored. Results: 76 patients were enrolled, median age 63 years (range 43–89), 42% female, 97% with metastatic disease, 9% having received adjuvant chemotherapy. The most frequen
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
Exciting Ph2 data in 1L mPDAC from Cantargia AB combining IL1RAP inh nadunolimab w/ gem/abraxane, published @CCR_AACR. N.B➡️naduno was to be next arm in @PanCAN #PrecisionPromise until FDA raised concerns abt dosing since initial trial was done in Europe https://t.co/VE4J1XvTlR
-
-
Mashup Score: 33
Background In patients with localized pancreatic ductal adenocarcinoma (PDAC) undergoing neoadjuvant therapy (NAT) and resection, selection of adjuvant chemotherapy (AC) is typically guided by high-…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
🚨New📄from @SylvesterCancer🫱🏽🫲🏾#CentralPancreasConsortium!How should we use pathologic lymph node metrics AFTER neoadjuvant tx &🔪in #PancreaticCancer pts➡️to guide adjuvant tx selection?Is LN➕/⛔️vity enough or LN ratio useful?Find out👉🏽https://t.co/4Fjgu3b9Rw @JofSurgOnc #pancsm https://t.co/JQ7WFYPZKi
-
-
Mashup Score: 23Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer - 9 month(s) ago
PURPOSE Using a real-world database with matched genomic-transcriptomic molecular data, we sought to characterize the distinct molecular correlates underlying clinical differences between patients with young-onset pancreatic cancer (YOPC; younger than 50 years) and patients with average-onset pancreatic cancer (AOPC; 70 years and older). METHODS We analyzed matched whole-transcriptome and DNA sequencing data from 2,430 patient samples (YOPC, n = 292; AOPC, n = 2,138) from the Caris Life Sciences database (Phoenix, AZ). Immune deconvolution was performed using the quanTIseq pipeline. Overall survival (OS) data were obtained from insurance claims (n = 4,928); Kaplan-Meier estimates were calculated for age- and molecularly defined cohorts. Significance was determined as FDR-corrected P values (Q) < .05. RESULTS Patients with YOPC had higher proportions of mismatch repair–deficient/microsatellite instability-high, BRCA2-mutant, and PALB2-mutant tumors compared with patients with AOPC, but
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
📈in early onset GI cancers esp colorectal & pancreatic is of grave concern👇🏽#GI24. An opportunity to🔌our recent manuscript detailing the distinct molecular landscape of young onset #PancreaticCancer in @JCOPO_ASCO➡️https://t.co/iWxdnWBGcQ. Read🧵here: https://t.co/WWEoiq70F4 https://t.co/GnjGlpFAxq
-
-
Mashup Score: 37Post-Doctoral Associate - 9 month(s) ago
Current Employees: If you are a current Staff, Faculty or Temporary employee at the University of Miami, please click here to log in to Workday to use the internal application process. To learn how to apply for a faculty or staff position using the Career worklet, please review this tip sheet. The SCCC department is seeking a Postdoc Associate. The Postdoc Associate will conduct research on specific areas of study as assigned. Prepares research reports and technical papers for publishing. Investigates the feasibility of applying a wide variety of scientific principles and theories. Maintains substantial knowledge of state-of-the-art principles and theories. Develops advanced analytical models and systems and provides solutions and analyses to support strategic and tactical decisions. Adheres to University and unit-level policies and procedures and safeguards University assets. This list of duties and responsibilities is not intended to be all-inclusive and may be expanded to include ot
Source: umiami.wd1.myworkdayjobs.comCategories: General Medicine News, Hem/OncsTweet-
🚨JOB alert! Interested in #HomologousRecombinationDeficiency (eg BRCA1/2), STING signaling, type 1 interferon-induced immunity, or #PancreaticCancer #pancsm? @PeterHoseinMD & I are hiring @SylvesterCancer. Come join us in☀️Miami! Spread the word, & apply: https://t.co/P8fFbDRI4U https://t.co/no9moYK3KK
-
Let's take steps together at PurpleStride! Please donate to our @SylvesterCancer team's effort in raising lifesaving $$ for #PancreaticCancer #pancsm research @PanCAN CC: @JulieFleshman @aberkenblit https://t.co/JRyiQnCOey